View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
 PRESS RELEASE

FRO - Grant of synthetic options

FRO - Grant of synthetic options Frontline plc ("Frontline" or the "Company") hereby announces that 362,284 synthetic options have today been granted to management and employees of the Company. The synthetic options will have a five-year term expiring May 27, 2030, and will vest over a three-year vesting period as follows: 1/3 of the synthetic options will vest on May 27, 20261/3 of the synthetic options will vest on May 27, 2027 1/3 of the synthetic options will vest on May 27, 2028 The  exercise price of the synthetic options  is USD 16.8 being the volume-weighted average price of the ...

 PRESS RELEASE

FRO - Q1 2025 Presentation

FRO - Q1 2025 Presentation Please find enclosed the presentation of Frontline plc´s first quarter 2025 results to be held on the webcast / conference call 23 May, 2025 at 15:00 CET. This information is subject to the disclosure requirements pursuant to section 5 – 12 of the Norwegian Securities Trading Act. Attachment

 PRESS RELEASE

FRO – First Quarter 2025 Results

FRO – First Quarter 2025 Results FRONTLINE PLC REPORTS RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2025 Frontline plc (the “Company”, “Frontline,” “we,” “us,” or “our”), today reported unaudited results for the three months ended March 31, 2025: Highlights  Profit of $33.3 million, or $0.15 per share for the first quarter of 2025.Adjusted profit of $40.4 million, or $0.18 per share for the first quarter of 2025.Declared a cash dividend of $0.18 per share for the first quarter of 2025.Reported revenues of $427.9 million for the first quarter of 2025.Achieved average daily spot time char...

 PRESS RELEASE

FRO – Invitation to Q1 2025 Results Conference Call and Webcast

FRO – Invitation to Q1 2025 Results Conference Call and Webcast Frontline plc.’s preliminary first quarter 2025 results will be released on Friday May 23, 2025, and a webcast and conference call will be held at 3:00 p.m. CET (9:00 a.m. U.S. Eastern Time). The results presentation will be available for download from the Investor Relations section at ahead of the conference call. In order to attend the conference call you may do one of the following: a. Webcast Go to the Investor Relations section at and follow the “Webcast” link, or access directly from the link below. b. Conference C...

Patrik Ling
  • Patrik Ling

Swedish Orphan Biovitrum (Buy, TP: SEK365.00) - Haemophilia the highli...

Q1 sales beat our forecast by 5% and adj. EBITA outperformed by 8%. Overall, we believe the highlight in the report was the stronger haemophilia result than expected, with solid growth in Altuvoct and a smaller decline for Elocta than forecast. The weak spot was Vonjo sales, which missed our estimate by 28% and consensus by 29%, with management citing stocking issues. We reiterate our BUY and SEK365 target price.

ABGSC Healthcare Research ... (+3)
  • ABGSC Healthcare Research
  • Alexander Krämer
  • Morten Larsen
ABGSC Healthcare Research ... (+3)
  • ABGSC Healthcare Research
  • Alexander Krämer
  • Morten Larsen
Jørgen Lian
  • Jørgen Lian

Frontline (Buy, TP: NOK280.00) - Front-row ticket to tanker potential

We believe the tanker fundamentals continue to look attractive, in particular for the VLCCs, with a highly manageable ~4% deliveries expected for 2025–2026. Further, we see potential positive catalysts in sanctions further restricting volumes transported on the dark fleet (possibly triggering scrapping postponed by shadow fleet deployment) and signs of a more aggressive volume strategy from OPEC+. Hence, we reiterate our BUY but have reduced out target price to NOK280 (295).

ABGSC Healthcare Research ... (+3)
  • ABGSC Healthcare Research
  • Julia Sundvall
  • Stefan Knutsson
Karl-Johan Bonnevier
  • Karl-Johan Bonnevier

Humana (Buy, TP: SEK52.00) - Growth agenda back in focus

The Q1 results were mixed, but with the financials now in good order, we see more of a growth focus ahead. We find management’s priorities logical, with our underlying forecast largely unchanged, but our 2025–2027e EPS cut by 6–2% on FX and non-cash items. We reiterate our BUY, but have trimmed our target price to SEK52 (53), focusing on Humana’s market opportunity, operating profile, financial outlook and valuation.

ABGSC Healthcare Research ... (+3)
  • ABGSC Healthcare Research
  • Alexander Krämer
  • Morten Larsen
ABGSC Healthcare Research ... (+3)
  • ABGSC Healthcare Research
  • Julia Sundvall
  • Stefan Knutsson
Jørgen Lian
  • Jørgen Lian

Another abrupt change

The US Trade Representative on 17 April published revised US port fees with significant changes to the initial proposal based on industry feedback. In its current form, the fees will primarily discourage use of Chinese-controlled maritime trade services to the US, and directly affect the use of Chinese-built vessels in US ports (with several considerable exemptions to avoid harm to US trade). The previous broader fees based on fleet composition and share of Chinese-built vessels has been scrappe...

ABGSC Healthcare Research ... (+3)
  • ABGSC Healthcare Research
  • Julia Sundvall
  • Stefan Knutsson
ABGSC Healthcare Research ... (+3)
  • ABGSC Healthcare Research
  • Alexander Krämer
  • Morten Larsen
 PRESS RELEASE

FRO – Filing of Annual Report

FRO – Filing of Annual Report  Frontline plc (the “Company”) announces the filing of its annual report for the year ended December 31, 2024. The annual report can be downloaded from the Company’s website or from the link below. Additionally, shareholders can request a hard copy of our complete audited financial statements free of charge by writing to us at:John Kennedy  8 Iris Building, 7th floor, Flat/Office 740B,3106, Limassol, Cyprus. or sending an e-mail to  April 7, 2025Frontline plcLimassol, Cyprus. Questions should be directed to: Lars H. Barstad: Chief Executive Officer, Front...

Patrik Ling
  • Patrik Ling

Swedish Orphan Biovitrum (Buy, TP: SEK365.00) - Slightly below consens...

We forecast a decent quarter, despite some difficult revenue comparables, with no manufacturing revenues, lower Elocta sales and lower Beyfortus royalties YOY, unlikely to be fully compensated by new product growth, such as for Altuvoct. Meanwhile, the company continues to invest in its recently launched products (and coming launches), which should be well known by the market. We reiterate our BUY and SEK365 target price.

ABGSC Healthcare Research ... (+3)
  • ABGSC Healthcare Research
  • Alexander Krämer
  • Morten Larsen

Frontline Plc: 1 director

A director at Frontline Plc bought 5,000 shares at 171.050NOK and the significance rating of the trade was 57/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly...

Jørgen Lian
  • Jørgen Lian

‘The times they are a-changin’

The recurring theme at our 18th Energy & Shipping Conference was geopolitical uncertainty and a potential trade war, warranting a wait-and-see approach, particularly on the Trump 2.0 effect. The consensus view pointed to high asset values, with no rush to the yards, aligning with below-NAV valuations across most of our coverage. However, panellists generally saw less downside risk than the 25% average discount to steel for our Tanker, Dry Bulk and Gas coverage. Overall, the day highlighted uncer...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch